{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:38Z","timestamp":1787020778071,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T00:00:00Z","timestamp":1536969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13048-018-0458-0","type":"journal-article","created":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T21:37:45Z","timestamp":1537047465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types"],"prefix":"10.1186","volume":"11","author":[{"given":"Masaki","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasa","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoso","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Nakatsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Mabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,15]]},"reference":[{"key":"458_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"458_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canlet.2011.05.022","volume":"309","author":"M Cohen","year":"2011","unstructured":"Cohen M, Petignat P. Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells. Cancer Lett. 2011;309:104\u20139.","journal-title":"Cancer Lett"},{"key":"458_CR3","unstructured":"NIH Surveillance, Epidemiology, and End Results Program Database. \n                    http:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html\n                    \n                  . Updated November, 2017."},{"issue":"5-6","key":"458_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1155\/2007\/309382","volume":"23","author":"Donna Badgwell","year":"2007","unstructured":"Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers 2007;23:397\u2013410.","journal-title":"Disease Markers"},{"key":"458_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.21037\/atm.2017.05.13","volume":"5","author":"M Montagnana","year":"2017","unstructured":"Montagnana M, Benati M, Danese E. Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective. Ann Transl Med. 2017;5:276.","journal-title":"Ann Transl Med"},{"key":"458_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402\u20138.","journal-title":"Gynecol Oncol"},{"key":"458_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1158\/1055-9965.EPI-15-1299","volume":"25","author":"F Leung","year":"2016","unstructured":"Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC Jr, et al. Validation of a novel biomarker panel for the detection of ovarian Cancer. Cancer Epidemiol Biomark Prev. 2016;25:1333\u201340.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"458_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/jcla.20340","volume":"23","author":"M Montagnana","year":"2009","unstructured":"Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal. 2009;23:331\u20135.","journal-title":"J Clin Lab Anal"},{"key":"458_CR9","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian Cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945\u201356.","journal-title":"Lancet"},{"key":"458_CR10","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"458_CR11","doi-asserted-by":"publisher","first-page":"26913","DOI":"10.3402\/jev.v3.26913","volume":"3","author":"J L\u00f6tvall","year":"2014","unstructured":"L\u00f6tvall J, Hill AF, Hochberg F, Buz\u00e1s EI, Di Vizio D, Gardiner C, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913.","journal-title":"J Extracell Vesicles"},{"key":"458_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-016-0536-0","volume":"15","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016;15:48.","journal-title":"Mol Cancer"},{"key":"458_CR13","first-page":"329","volume":"17","author":"M Miyanishi","year":"2007","unstructured":"Miyanishi M, Mandai M, Matsumura N, Yamaguchi K, Hamanishi J, Higuchi T, et al. Immortalized ovarian surface epithelial cells acquire tumorigenicity by Acrogranin gene overexpression. Oncol Rep. 2007;17:329\u201333.","journal-title":"Oncol Rep"},{"key":"458_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1158\/1541-7786.MCR-16-0191","volume":"15","author":"K Nakamura","year":"2017","unstructured":"Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15:78\u201392.","journal-title":"Mol Cancer Res"},{"key":"458_CR15","first-page":"e3037","volume":"59","author":"C L\u00e4sser","year":"2012","unstructured":"L\u00e4sser C, Eldh M, L\u00f6tvall J. Isolation and characterization of RNA-containing exosomes. J Vis Exp. 2012;59:e3037.","journal-title":"J Vis Exp"},{"key":"458_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi H, Ekstr\u00f6m K, Bossios A, Sj\u00f6strand M, Lee JJ, L\u00f6tvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654\u20139.","journal-title":"Nat Cell Biol"},{"key":"458_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"T Onda","year":"2016","unstructured":"Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan clinical oncology group study JCOG0602. Eur J Cancer. 2016;64:22\u201331.","journal-title":"Eur J Cancer"},{"key":"458_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jamcollsurg.2003.06.004","volume":"197","author":"P Morice","year":"2003","unstructured":"Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg. 2003;197:955\u201363.","journal-title":"J Am Coll Surg"},{"key":"458_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943\u201353.","journal-title":"N Engl J Med"},{"key":"458_CR20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/cncr.24152","volume":"115","author":"C Tian","year":"2009","unstructured":"Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a gynecologic oncology group study. Cancer. 2009;115:1395\u2013403.","journal-title":"Cancer"},{"key":"458_CR21","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ncb1800","volume":"10","author":"J Skog","year":"2008","unstructured":"Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470\u20136.","journal-title":"Nat Cell Biol"},{"key":"458_CR22","first-page":"1570","volume":"7","author":"D Mo","year":"2015","unstructured":"Mo D, Gu B, Gong X, Wu L, Wang H, Jiang Y, et al. miR-1290 is a potential prognostic biomarker in non-small cell lung cancer. J Thorac Dis. 2015;7:1570\u20139.","journal-title":"J Thorac Dis"},{"key":"458_CR23","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1158\/1078-0432.CCR-12-3092","volume":"19","author":"A Li","year":"2013","unstructured":"Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013;19:3600\u201310.","journal-title":"Clin Cancer Res"},{"key":"458_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2012.10.038","volume":"329","author":"J Wu","year":"2013","unstructured":"Wu J, Ji X, Zhu L, Jiang Q, Wen Z, Xu S, et al. Up-regulation of microRNA-1290 impairs cytokinesis and affects the reprogramming of colon cancer cells. Cancer Lett. 2013;329:155\u201363.","journal-title":"Cancer Lett"},{"key":"458_CR25","unstructured":"miRTargetLink Human Database. Available at: \n                    https:\/\/ccb-web.cs.uni-saarland.de\/mirtargetlink\/\n                    \n                   Updated June, 2018."},{"key":"458_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.bbrc.2014.10.118","volume":"454","author":"J Wang","year":"2014","unstructured":"Wang J, Liao QJ, Zhang Y, Zhou H, Luo CH, Tang J, et al. TRPM7 is required for ovarian cancer cell growth, migration and invasion. Biochem Biophys Res Commun. 2014;454:547\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"458_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00428-013-1375-7","volume":"462","author":"HT Xu","year":"2013","unstructured":"Xu HT, Liu Y, Liu SL, Miao Y, Li QC, Wang EH. TC-1 (C8orf4) expression is correlated with differentiation in ovarian carcinomas and might distinguish metastatic ovarian from metastatic colorectal carcinomas. Virchows Arch. 2013;462:281\u20137.","journal-title":"Virchows Arch"},{"key":"458_CR28","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3892\/or.2014.3072","volume":"31","author":"B Wang","year":"2014","unstructured":"Wang B, Li J, Ye Z, Li Z, Wu X. N-myc downstream regulated gene 1 acts as a tumor suppressor in ovarian cancer. Oncol Rep. 2014;31:2279\u201385.","journal-title":"Oncol Rep"},{"key":"458_CR29","first-page":"56","volume":"3","author":"G Hu","year":"2012","unstructured":"Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological properties and therapeutic potential. Front Genet. 2012;3:56.","journal-title":"Front Genet"},{"key":"458_CR30","doi-asserted-by":"publisher","first-page":"e92921","DOI":"10.1371\/journal.pone.0092921","volume":"9","author":"H Ogata-Kawata","year":"2014","unstructured":"Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al. Circulating Exosomal microRNAs as biomarkers of Colon Cancer. PLoS One. 2014;9:e92921.","journal-title":"PLoS One"},{"key":"458_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ygyno.2008.04.033","volume":"110","author":"DD Taylor","year":"2008","unstructured":"Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13\u201321.","journal-title":"Gynecol Oncol"},{"key":"458_CR32","doi-asserted-by":"publisher","first-page":"89811","DOI":"10.18632\/oncotarget.20688","volume":"8","author":"A Yokoi","year":"2017","unstructured":"Yokoi A, Yoshioka Y, Hirakawa A, Yamamoto Y, Ishikawa M, Ikeda S, et al. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget. 2017;8:89811\u201323.","journal-title":"Oncotarget"},{"key":"458_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2017.11.005","volume":"148","author":"JS Shah","year":"2018","unstructured":"Shah JS, Gard GB, Yang J, Maidens J, Valmadre S, Soon PS, et al. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer. Gynecol Oncol. 2018;148:181\u20138.","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-018-0458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-018-0458-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-018-0458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T19:11:23Z","timestamp":1568488283000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-018-0458-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,15]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1186\/s13048-018-0458-0","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,15]]},"assertion":[{"value":"28 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of Osaka University Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"81"}}